Increased soluble interleukin-2 receptors in lung cancer patients
Author Information
Author(s): P. Marino, M. Cugnol, A. Preatoni, P. Cori, A. Rosti, L. Frontini, M. Cicardi
Primary Institution: University of Milan and Ospedale S. Paolo
Hypothesis
Do changes in soluble interleukin-2 receptors relate to the type or stage of lung cancer?
Conclusion
Soluble interleukin-2 receptors are elevated in lung cancer, but their levels do not correlate with histological type or disease stage.
Supporting Evidence
- Serum levels of soluble interleukin-2 receptors were significantly higher in lung cancer patients compared to healthy controls.
- No significant differences in soluble interleukin-2 receptor levels were found among different histological types of lung cancer.
- The study included patients with both small cell and non-small cell lung cancer.
Takeaway
Patients with lung cancer have higher levels of a certain protein in their blood, but it doesn't matter what type of lung cancer they have.
Methodology
Measured soluble interleukin-2 receptors in serum using an ELISA test and compared levels between lung cancer patients and healthy controls.
Limitations
The study did not include patients who had received prior treatment, and the biological relevance of soluble interleukin-2 receptors remains unclear.
Participant Demographics
43 Caucasian patients (33 males and 10 females) aged 63 ± 10 years.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website